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Abstract
Background: Resveratrol, a natural polyphenolic compound, was shown to protect rodents against high-fat-diet 
induced diabesity by boosting energy metabolism. To the best of our knowledge, no data is yet available on the effects 
of resveratrol in non-human primates. Six non-human heterotherm primates (grey mouse lemurs, Microcebus murinus) 
were studied during four weeks of dietary supplementation with resveratrol (200 mg/kg/day) during their winter body-
mass gain period. Body mass, spontaneous energy intake, resting metabolic rate, spontaneous locomotor activity and 
daily variations in body temperature were measured. In addition, the plasma levels of several gut hormones involved in 
satiety control were evaluated.
Results: Resveratrol reduced the seasonal body-mass gain by concomitantly decreasing energy intake by 13% and 
increasing resting metabolic rate by 29%. Resveratrol supplementation inhibited the depth of daily torpor, an 
important energy-saving process in this primate. The daily amount of locomotor activity remained unchanged. Except 
for an increase in the glucose-dependent insulinotropic polypeptide, a gut hormone known to promote mobilization 
of fat stores, no major change in satiety hormone plasma levels was observed under resveratrol supplementation.
Conclusions: These results suggest that in a non-human primate, resveratrol reduces body-mass gain by increasing 
satiety and resting metabolic rate, and by inhibiting torpor expression. The measured anorectic gut hormones did not 
seem to play a major role in these observations.
Background
Obesity stems from a prolonged imbalance between the
level of energy intake and energy expenditure, with the
resultant surplus being stored as lipids predominantly in
adipose tissue, but also in muscle and liver tissue, trigger-
ing features of the metabolic syndrome. Understanding
the factors which regulate both energy intake and expen-
diture, such as environmental/lifestyle manipulations or
pharmaceuticals, is an important step towards develop-
ing obesity treatments.
The physiological benefits of resveratrol (3,4',5-trihy-
droxystilbene or RSV), a natural polyphenol, are cur-
rently under intensive investigation. Resveratrol is
produced by plants in response to infection by the patho-
gen Botrytis cinerea [1]. It is also induced in response to a
variety of stress conditions (climate, exposure to ozone,
sunlight and heavy metals) [2]. Presently, it has been
detected in more than 70 plant species, including grapes,
peanuts, berries and pines [2]. Resveratrol is able to acti-
vate nicotinamide adenosine dinucleotide-dependent
deacetylase SIRT1 (Silent mating type Information Regu-
lation 2 homologue Type 1), one of the seven mammalian
sirtuins [3,4] involved in glucose homeostasis and lipid
metabolism. This activation of SIRT1 by RSV seems to
prevent obesity by inducing oxidative mitochondrial
metabolism [5] and reduced insulin resistance [6] in mice
on a high-caloric diet. In the same way, RSV minimizes
hyperglycaemia in diet-induced obese and diabetic mice
[7], and dyslipidemia in the experimental model of obese
Zucker rats. These rodent models are widely used as ani-
mal models of obesity and type 2 diabetes which present
many features of the human metabolic syndrome [8]. The
validity of information obtained in primates, particularly
in humans, is still under debate because the experimental
protocols used in the preliminary studies were quite dif-
ferent from each other [9]. Moreover, recent works have
demonstrated that RSV supplementation mimics caloric
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restriction in mice [10], suggesting that RSV could be a
good candidate for the development of obesity therapies.
However, most RSV studies focused on changes in
energy expenditure and its related cellular mechanisms
[11,12] and were mainly obtained from genetically modi-
fied mouse models of obesity [13] or in the context of a
high-fat diet [14,11]. The effects of RSV on spontaneous
food intake and its regulation are still unclear and still
unknown in primates.
The aim of the present study was thus to determine the
effects of a four-week RSV supplementation on energy
metabolism and spontaneous food intake in a non-
human primate, the grey mouse lemur (Microcebus muri-
nus), which demonstrates seasonal spontaneous obesity.
Grey mouse lemurs present high photoperiod-dependent
v a r i a t i o n s  i n  b o d y  m a s s  a s s o c i a t e d  w i t h  e n e r g y  s a v i n g
mechanisms, in particular a phase of heterothermia dur-
ing their daily resting period. When exposed to a short
photoperiod, mouse lemurs display a fast and linear
body-mass gain (about 6-8 g/week) associated with a high
caloric intake. In just a few weeks, a near 100% increase in
body mass is observed due to high levels of fat storage,
while the duration and depth of daily hypothermia bouts
increase [15,16].
The effect of RSV supplementation on body mass, rest-
ing metabolic rate (RMR), daily body temperature (Tb)
variations and spontaneous food intake in the grey mouse
lemur was explored to investigate of the hypothesis that
RSV supplementation will affect the time courses of pre-
wintering fattening mechanisms in this primate. Because
previous studies on mouse lemurs have suggested that
several gut hormones may be related to the pre-wintering
fattening phase and to the daily heterothermia expression
[17], we also tested the effects of RSV supplementation
on several gut-derived peptide hormones that are
involved in numerous aspects of fuel homeostasis [18].
We measured glucagon-like peptide 1 (GLP-1), pancre-
atic polypeptide (PP), peptide YY (PYY) and glucose-
dependent insulinotropic polypeptide (GIP). Glucagon-
like peptide 1 and PYY were shown to decrease energy
expenditure and food intake [19]. Conversely, PP and GIP
induced an increase in energy expenditure, motor activity
and mobilization of fat stores [20]. Consequently, possi-
ble relationships between the key parameters involved in
energy balance regulation and gut hormones in grey
mouse lemurs were also investigated.
Results
During the control week prior to RSV supplementation,
the studied animals presented an average body-mass gain
of 6.2 ± 1.3% (1.2 g/d) from their initial mass (133 ± 4 g).
At the end of the four weeks of RSV supplementation, the
body-mass gain was gradually suppressed to 1.0 ± 0.3%
(0.5 g/d, F = 14.0, df = 4, p = 0.007, Figure 1A). A 13%
decrease in spontaneous food intake was noted from the
third week of RSV treatment (from 121.4 kJ/d to 104.7 kJ/
d, F = 10.4, df = 4, p = 0.035, Figure 1B). The RMR
increased by 29% after four weeks of RSV treatment com-
pared to the control period (F = 12.7, df = 4, p = 0.013,
Figure 1C). Total daily locomotor activity (LA) was not
modified by RSV treatment (164 ± 23 a.u. in the control
week vs. 168 ± 12 a.u. in the fourth week of treatment, F =
0.4, df = 4, p = 0.980, Figure 1D). A representative profile
of the weekly average of variations in Tb of one mouse
lemur is represented in Figure 2A. The mouse lemurs
exhibited a significant increase in their mean Tb during
the diurnal phase (Tb day) with a gain of 1.0 ± 0.3°C
between the control and the fourth week of treatment
(34.7 ± 0.5°C vs. 35.6 ± 0.1°C, F = 14.3, df = 4, p = 0.006).
The minimal Tb value (Tb min) of the animals increased
by 1.5 ± 0.6°C between the control and the fourth week of
treatment (32.4 ± 0.8°C vs. 33.9 ± 0.4°C, F = 11.1, df = 4, p
= 0.026). The amplitude of the phase of daily hypo-
thermia was greatly reduced in response to RSV supple-
mentation. On the other hand, no significant change in
the mean Tb during the active nocturnal phase (Tb night)
was found in response to RSV supplementation (36.4 ±
0.1°C vs. 36.6 ± 0.1°C, F = 3.3, df = 4, p = 0.504) (Figure
2B).
No significant time-course change was reported for
GLP-1, PP and PYY levels. Only the GIP level was signifi-
cantly increased by RSV after four weeks of supplementa-
tion (104 ± 14 pg/ml in the control week vs. 175 ± 39 pg/
ml in the fourth week, F = 11.6, df = 4, p = 0.021) (Table
1). Although trends are visible, the increased inter-indi-
vidual variability observed during the treatment (from
21% to 61%, F = 14.3, df = 4, p = 0.002) did not allow any
significant conclusion to be reached. Lastly, no significant
correlation could be found between the variations in gut
hormones and the variations in body-mass gain, food
intake or RMR (Table 2).
Discussion
The main findings of this study were: 1) a four-week res-
veratrol supplementation had significant effects on
energy metabolism in the mouse lemur, characterized by
a reduction in seasonal body-mass gain associated with
an increase in resting metabolic rate and a decrease in
food intake; 2) the response to resveratrol supplementa-
tion mainly involved a strong reduction of daily hetero-
thermia expression with no change in the daily amount of
locomotor activity; 3) despite the fact that glucose-
dependent insulinotropic polypeptide (GIP) values
increased during resveratrol supplementation, no corre-
lation was evidenced between the other tested gut hor-
mones and changes in energy balance parameters.
Resveratrol supplementation was given to mouse
lemurs at the very time of seasonal fattening induced byDal-Pan et al. BMC Physiology 2010, 10:11
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Figure 1 Resveratrol effects on parameters of energy balance. Six male mouse lemurs were observed during one week of ad libitum feeding (Con-
trol), followed by four weeks of RSV supplementation to the ad libitum feeding (RSV1, 2, 3 and 4). The curves represent the evolution with time of food 
intake (A), body-mass gain (B), resting metabolic rate (RMR) (C) and daily amount of locomotor activity (LA) (D). Values are given as mean ± SEM. Res-
veratrol supplementation induced a significant decrease in food intake and body-mass gain associated with an increase in RMR. The amount of LA 
was not modified by the treatment.
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Figure 2 Resveratrol effects on body temperature of the animals. Six male mouse lemurs were observed during one week of ad libitum feeding 
(Control), followed by four weeks of RSV supplementation to the ad libitum feeding (RSV1, 2, 3 and 4). Panel (A) represents the average daily profiles 
of the Tb of one representative mouse lemur during the control week and during each week of RSV supplementation. Panel (B) illustrates the evolution 
of the diurnal (Tb day), nocturnal (Tb night) and minimal (Tb min) body temperatures according to the duration of treatment. Values are given as mean 
± SEM. Resveratrol supplementation induced a clear reduction of the phase of daily torpor revealed by the significant increase in Tb day and Tb min 
values over the course of treatment.
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exposure to short day lengths. This period corresponds to
an increase in both spontaneous food intake and fre-
quency of deep t orpor , leading t o fast body mass gain
through fat accumulation. Moreover, the resting meta-
bolic rate and locomotor activity decrease, reinforcing
the energy saving processes. Resveratrol supplementation
appeared to limit all these energy saving mechanisms by
acting more specifically on food intake and daily hypo-
thermia bouts without change in locomotor activity.
The observed decrease in food intake in mouse lemurs
cannot be related to the palatability of resveratrol as the
mouse lemurs were not found to be averse to resveratrol
prior to the experiment. It is more likely that an aversive
palatability of resveratrol would have led to an immediate
reduction in food intake which was not observed. How-
ever, the effects on food intake might have been related to
the dose of resveratrol given. The dosage level adminis-
tered in this study (200 mg/kg) was selected from studies
in the literature on rodents, and was intermediate
between the 40 mg/kg of Baur et al. [14] and the 400 mg/
kg of Lagouge et al. [12]. This dose was carefully mixed in
the food and, since the animals tended to eat less than
provided, the actual ingested dose of resveratrol was
below 200 mg/kg. The amount of resveratrol ingested by
the animals was 96.1% in the first week and 84% in the
fourth week (corresponding to an equivalent of 192 mg/
kg/day and 168 mg/kg/day, respectively). These amounts,
based on the existing literature, appeared sufficiently
high to be effective in mammals [21-23]. However, the
observed satiety in resveratrol-supplemented mouse
lemurs may be a sensibility response specific to this spe-
cies or to primates.
Although the change in food intake could explain the
reduction of seasonal body-mass gain, resveratrol supple-
mentation significantly affected the body temperature
patterns in the mouse lemur. Average values of energy
savings by daily torpor in this species have been esti-
mated to be about 40-70% as compared to the mainte-
nance of normothermia [24,25]. Under resveratrol
supplementation, the depth and the duration of daily tor-
por decreased and were associated with an increase in
both body temperature and resting metabolic rate during
the daily resting period. In contrast, body temperature
values during the night active phase were not modified,
and nor was locomotor activity. The decrease in energy
savings during the daily diurnal rest would thus contrib-
ute to the reduction in body-mass gain under resveratrol
supplementation.
Table 1: Resveratrol effects on the levels of the different gut hormones tested during the four weeks of treatment.
Gut 
hormones
Control RSV1 RSV2 RSV3 RSV4 Friedman 
test
GIP 104 ± 14 123 ± 25 168 ± 28 187 ± 33 175 ± 39 F = 11.6, df = 4, 
p = 0.021
GLP-1 673 ± 25 705 ± 34 899 ± 139 1088 ± 293 1080 ± 295 F = 0.7, df = 4, 
p = 0.949
PP 205 ± 17 206 ± 22 193 ± 18 148 ± 36 140 ± 33 F = 4.2, df = 4, 
p = 0.385
PYY 298 ± 11 299 ± 16 329 ± 23 293 ± 47 261 ± 57 F = 1.8, df = 4, 
p = 0.779
The gut hormone levels investigated were glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), pancreatic 
polypeptide (PP) and peptide YY (PYY). RSV1, 2, 3 and 4 represent the four successive weeks of RSV treatment. Values are expressed in pg/ml 
and they are given as mean ± SEM (n = 6)
Table 2: Correlations between the variations in gut hormone levels and the variations in energy parameters.
Gut hormones Body mass gain Food intake Resting metabolic rate
GIP R = 0.260, p = 0.658 R = 0.260, p = 0.658 R = -0.200, p = 0.714
GLP-1 R = 0.086, p = 0.919 R = 0.543, p = 0.297 R = 0.143, p = 0.803
PP R = -0.314, p = 0.564 R = 0.657, p = 0.175 R = 0.486, p = 0.356
PYY R = -0.029, p = 1.000 R = 0.029, p = 1.000 R = 0.086, p = 0.919
Correlations were analysed between gut hormone levels (glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 
(GLP-1), pancreatic polypeptide (PP) and peptide YY (PYY)) and variations in body mass gain, food intake and resting metabolic rate between 
the control week and the fourth week of RSV supplementation (all results are non significant) (n = 6).Dal-Pan et al. BMC Physiology 2010, 10:11
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No such effect of resveratrol has been shown in mice,
for which no change in food intake or body temperature
was observed [11,13]. However, these data originate from
experimentally-induced obesity and it is likely that the
responses observed in mouse lemurs rely on specific life-
history traits of this primate, which has developed high
seasonal energy saving mechanisms and exhibits pre-
wintering spontaneous obesity.
Resveratrol activates mammalian sirtuins, more specifi-
cally SIRT1, which is involved in glucose homeostasis and
lipid metabolism. In mice exposed to a high-fat diet or in
ob/ob mice, resveratrol was shown to protect mice from
diet-induced metabolic disorders [12,13,26] by mimick-
ing some effects of caloric restriction. Likewise, resvera-
trol and assimilated SIRT1 activators have been proposed
as potential treatments for type 2 diabetes in mice models
[14,12,27,28]. The effects of resveratrol have been sug-
gested to depend on an increase in oxidative mitochon-
drial metabolism [14] and on enhanced fat oxidation [11],
leading to an increase in energy expenditure. Interest-
ingly, SRT1720, which activates SIRT1 by four fold in
comparison to resveratrol, induces a significant decrease
in fat mass without a change in food intake in mice [11].
In the mouse lemur, concomitantly to an increase in
energy expenditure through decreasing hypothermia
bouts and increasing metabolism, resveratrol might have
a direct negative effect on fat storage.
Due to their involvement in satiety and satiation pro-
cesses [18,29,30], several gut hormones have been mea-
sured in resveratrol-supplemented mouse lemurs. No
significant change was recorded after four weeks for the
glucagon-like peptide 1 and the peptide YY, two gut hor-
mones involved in the reduction of food intake and
energy expenditure [31-34]. Conversely, the two other gut
hormones are known to induce an increase in energy
expenditure. The pancreatic polypeptide increases sati-
ety, thus leading to a loss in body mass [20] and the glu-
cose-dependent insulinotropic polypeptide (GIP) was
shown to induce an increase in exploratory behaviour
and performance in some motor function tests in a trans-
genic mouse that over-expressed GIP [35]. Only GIP sig-
nificantly increased with resveratrol supplementation.
Data emerging from studies in animal models and cul-
tured human fat cells support a physiological role for GIP
in fat cell metabolism, leading to the mobilization of fat
stores [17,36]. Such effects might have contributed to the
reduction in body-mass gain by limiting fat storage in
supplemented mouse lemurs. The observed effect of res-
veratrol on food intake in the mouse lemur appears to be
independent of changes in anorexic gut hormones, but
the high observed inter-individual variability in our study
does not allow definite conclusions to be reached. More-
over, because sampling was performed at a single point in
fasted animals during the diurnal rest, changes may have
been missed.
Resveratrol has been studied as a potential mimetic of
caloric restriction [4]. However, caloric restriction
decreases the metabolic rate [37], whereas resveratrol
had the opposite effect [12]. From previous studies using
moderate caloric restriction in wintering mouse lemurs
[17], the effects of resveratrol significantly differed from
changes observed in caloric-restricted animals. In the
mouse lemurs, caloric restriction led to an increase in the
duration and depth of daily torpor bouts. These body
temperature adjustments were efficient at preventing
body-mass loss and were not associated with changes in
gut hormones [17].
Conclusion
In conclusion, we demonstrated for the first time the
short-term effects of resveratrol on the metabolism of an
heterothermic primate. Resveratrol activates energy
expenditure by inducing an increase in resting metabolic
rate and a decrease in torpor patterns that play key roles
in energy saving in this primate. Moreover, resveratrol
had a satiety effect in this primate that reduced their
spontaneous food intake. All of these changes partici-
pated in the limitation of pre-wintering fattening pro-
cesses in which the increase in the glucose-dependent
insulinotropic polypeptide levels would play an additive
role. These results provide novel information on the
potential effects of resveratrol on energy metabolism and
control of body mass in a primate.
Methods
Animals and animal care
We used six male grey mouse lemurs (Microcebus muri-
nus, Cheirogaleidae, primates) born in a laboratory
breeding colony in Brunoy, France (Agreement # 962773)
from a population originally caught 40 years ago on the
southwest coast of Madagascar. The animals were 3-year-
old adults and presented a mean ± standard error of the
mean (SEM) body mass of 133 ± 4 g. Conditions were
constant in respect to ambient temperature (25°C), rela-
tive humidity (55%), and ad libitum food availability.
Behavioural and physiological seasonal changes in mouse
lemurs are dependent on the photoperiod and are repro-
duced in captivity using an artificial photoperiodic regi-
men. In the breeding colony, animals were exposed to an
artificial photoperiodic regimen consisting of alternating
six-month periods of Malagasy winter-like short-day
lengths (light:dark 10:14) and Malagasy summer-like
long-day lengths (light:dark 14:10). Animals were studied
during the five weeks following the shift from long to
short day lengths corresponding to the pre-wintering fat-
tening period. To minimize social influences, the animalsDal-Pan et al. BMC Physiology 2010, 10:11
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were housed individually in cages (0.4 × 0.4 × 0.6 m) pro-
vided with nesting materials, and were separated from
each other by wooden partitions. Each week and just
before the daily food allotment, animals were weighed
inside their nest box, to avoid any stress, using a balance
accurate to 1 g.
All animals were fed ad libitum during one week, with
fresh fruit (bananas and apples) and a mixture of cereals,
milk and eggs, providing them with a total of 126 kJ per
day . The cereals were composed of 60% carbohydrates,
10% proteins and 30% lipids. The cereals were primarily
wheat flour (96%). The mixture was introduced 1 h before
the beginning of the animal's nocturnal active phase (Fig-
ure 3A). Water was always given ad libitum. During the
following four weeks (RSV1, RSV2, RSV3 and RSV4), the
animals were fed the same as above but 200 mg/kg of RSV
(Sequoia Research Products, United Kingdom) per day
was added to the mixture. Prior to the study, we moni-
tored the food intake of the six animals presented with a
choice between a bowl of control food and a bowl of food
supplemented with 200 mg/kg/day of RSV. Food was pro-
vided ad libitum in both bowls. Food intake was assessed
by weighing the daily leftovers and correcting for water
evaporation (calculated previously with the control mix-
ture under the same environmental conditions). The
average daily amounts of food eaten were similar between
control and RSV supplemented groups (t = 1.738, df = 5,
p = 0.143), evidencing no significant difference in the pal-
atability of the mixtures. To determine the exact quantity
of food ingested by the animals, daily leftovers were
Figure 3 Experimental timetable. A) The activity phase (17h-7h) and the resting phase (7h-17h) are represented in this schematic profile of body 
temperature variations of one animal during one day. The animals were followed for five weeks: one control week and four weeks with RSV supple-
mentation (200 mg/kg/day). The mouse lemurs were fed daily one hour before the beginning of their active phase during the five-week study. Blood 
sampling and measurement of the resting metabolic rate (RMR) were carried out once a week (each one on a different day) during the control period 
and each week of RSV treatment during their daily resting period, 4-6 h after the beginning of the light period to minimize the influence of circadian 
variations. B) This long-term experimental time line shows when the telemetry surgery, acclimation and first experiments were performed. The telem-
etry surgery was performed two weeks before the beginning of the short day period to allow animals to recover before beginning the experiment. 
The white arrows represent the moment when blood sampling, measurement of resting metabolic rate (RMR) and body weight were undertaken 
(once a week). The body temperature (Tb) and locomotor activity (LA) were continuously recorded during the five weeks from the shift to short day 
period.
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weighed and corrected for water evaporation as with the
palatability control. All the procedures were carried out
in accordance with the European Communities Council
Directive (86/609/EEC). All the experiments were done
under personal licence to experiment on mouse lemurs,
delivered by the Ministry of Education and Science after
approval of a local Ethics Committee (n° 91-305, issued
20 July, 2006).
Resting metabolic rate
Oxygen consumption was measured in a closed indirect
calorimetry system. Measurements on post-absorptive
animals were made daily during their resting period, 4-6
h after the beginning of the light period to minimize the
influence of circadian variations (Figure 3A). The animals
were trained to nest in 2.5 l opaque respiratory chambers
with a woven floor to absorb any urine. The respiratory
chamber was placed in a cabinet at a controlled ambient
temperature of 25.0 ± 0.5°C, a value within the ther-
moneutral zone defined for the mouse lemur [38]. After a
20 min habituation phase with a constant air flow (2 l/
min) drawn through the respirometry chamber from bot-
tom to top, the chamber was closed for a 40-min period.
The air was dried prior to analysis using a silica gel. The
VO2 consumed by the animal was calculated from initial
and final concentrations of O2 in the chamber which were
measured from dried gas using a SERVOMEX 570A para-
magnetic gas analyser (Servomex Ltd., England) (accu-
racy 0.01% O2). Calculations were made in Standard
Temperature and Pressure, Dry and, the daily atmo-
spheric humidity was accounted for. The oxygen analyser
was routinely calibrated with N2  and atmospheric air
assuming 21.00% O2 as recommended by the manufac-
turer. Oxygen consumption was expressed as ml O2/h.
The animals were weighed before each measurement.
Oxygen consumption was corrected for the body weight
of the animal [39]. Body temperature was not measured
before the experiment to avoid disturbing sleeping ani-
mals but males never enter deep torpor at an ambient
temperature of 25°C [40]. However, O2 consumption at
25°C cannot be defined as basal because the body tem-
perature varies in the grey mouse lemur, thus values were
referred to as resting metabolic rate (RMR) [15]. The val-
ues are given as mean ± SEM.
Recording of locomotor activity and body temperature
The grey mouse lemur is a nocturnal species exhibiting
h i gh  l ev e ls  o f  l oc o m o t o r  a ct i vi t y  ( LA )  d u ri n g  t h e  da r k
period and complete rest during the light period. Under
exposure to short days, the daily rhythm of body temper-
ature (Tb) in the mouse lemur is characterized by high Tb
values during the active period and, before the onset of
the light phase, a rapid and linear drop in Tb reaching
minimal values after 3-4 hours. This hypothermia bout is
followed by a spontaneous re-warming to normothermic
Tb levels until the following dark phase (Figure 3A).
The recording of LA and Tb was obtained by telemetry
at a constant ambient temperature of 25°C. A small tele-
metric transmitter weighing 2.5 g (model TA10TA-F20,
DataScience Co. Ltd, Minnesota, USA) was implanted
into the visceral cavity under ketamine anaesthesia (Imal-
gene, 100 mg/kg ip, Merial, France). Telemetry surgeries
were performed 15 days before the beginning of the short
day period. After surgery, the animals were returned to
their home cage and allowed to recover for 15 days before
starting the experiment and the continuous recording of
Tb from the beginning of the short day period. Total
recovery was checked by visual inspection to ensure com-
plete healing of the surgical incision and by verification of
a stable daily pattern of Tb variations. Recording began in
the first week following the shift to the short photoperiod
(Figure 3B). A receiver board was positioned in the cage
and LA (expressed in arbitrary units, a.u.) was continu-
ously recorded during this interval by two antennas
located in the receiver board which detected vertical and
horizontal movements (X-Y coordinate system, Data-
quest Lab Pro v. 3.0, Data Science Co. Ltd, Minnesota,
USA). The Tb (in°C) of the animals was recorded every
10 min. The following parameters were analysed: daily
amount of LA, mean Tb during the active nocturnal
phase (Tb night), mean Tb during the resting diurnal
phase (Tb day) and the minimal Tb value (Tb min).
Hormonal assays
Blood sampling was carried out once a week during the
control period and in each week of RSV treatment 4-6 h
after the beginning of the light period to minimize the
influence of circadian variations (Figure 3A). The blood
samples were taken via the saphenous vein, without
anaesthesia, before food allotment. The volume of blood
sampled was 100 μl and that represented less than 2% of
the total blood volume of the animals. The blood samples
were centrifuged at 7000 rpm at 4°C for 30 min. The
plasma was stored at -20°C according to the assay proce-
dure. Levels of glucagon-like peptide 1 (GPL-1), pancre-
atic polypeptide (PP), peptide YY (PYY) and glucose-
dependent insulinotropic polypeptide (GIP) were mea-
sured in duplicate using the human gut hormones multi-
plex panel (LincoplexTM Multiplex Assays, Bioscience)
and Luminex technology at the Saint Antoine Hospital in
Paris dedicated to micro-assays in small animals (IRSSA,
INSERM, IFR65, France), as previously described [17].
The average recoveries of known quantities of standard
peptides (taken at the low, medium and high concentra-
tions given in the assay) added to mouse lemur plasma
were 89% for GIP, 83% for GLP1, 88% for PP and 107% for
PYY. Inter-assay and intra-assay coefficients of variation
were < 19% and < 11%, respectively.Dal-Pan et al. BMC Physiology 2010, 10:11
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Page 9 of 10
Statistics
All values are expressed as mean ± SEM. W e used the
Friedman test to assess significant variations in all of the
studied parameters. Comparisons were considered to dif-
fer significantly when p < 0.05. Possible correlations
between the energy balance parameters and gut hormone
levels were assessed by Spearman's correlation test. All
statistical computations were performed using SYSTAT
for Windows (V9, SPSS Inc., Illinois, USA).
Abbreviations
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